Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
Authors
Keywords
-
Journal
EXPERIMENTAL DERMATOLOGY
Volume 27, Issue 7, Pages 737-747
Publisher
Wiley
Online
2018-04-29
DOI
10.1111/exd.13676
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of IL 23 in the treatment of psoriasis
- (2017) Lluís Puig Expert Review of Clinical Immunology
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis
- (2017) G. Girolomoni et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
- (2016) George E. Fragoulis et al. Annual Review of Medicine
- Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial
- (2016) Britton Trabert et al. INTERNATIONAL JOURNAL OF CANCER
- IL-23 Inhibits Melanoma Development by Augmenting DNA Repair and Modulating T Cell Subpopulations
- (2016) Tahseen H. Nasti et al. JOURNAL OF IMMUNOLOGY
- Increased expression of interleukin-23 associated with progression of colorectal cancer
- (2016) Wan-Hsiang Hu et al. JOURNAL OF SURGICAL ONCOLOGY
- Keratoacanthoma (KA): An update and review
- (2016) Bartlomiej Kwiek et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- IL-12 protects from psoriasiform skin inflammation
- (2016) Paulina Kulig et al. Nature Communications
- The Risk of Cancer in Patients With Psoriasis
- (2016) Zelma C. Chiesa Fuxench et al. JAMA Dermatology
- Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
- (2015) K. Reich et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States
- (2015) A.B. Kimball et al. BRITISH JOURNAL OF DERMATOLOGY
- Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer
- (2015) Lavinia Nardinocchi et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
- (2015) James G. Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Langerhans Cells Facilitate UVB-Induced Epidermal Carcinogenesis
- (2015) Julia M. Lewis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody
- (2015) Sanjaya Singh et al. mAbs
- Clinical improvement in psoriasis with specific targeting of interleukin-23
- (2015) Tamara Kopp et al. NATURE
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
- (2015) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial
- (2015) Danyelle A. Winchester et al. PROSTATE
- Interleukin-12 and Interleukin-6 Gene Polymorphisms and Risk of Bladder Cancer in the Iranian Population
- (2014) Nader Ebadi et al. Asian Pacific Journal of Cancer Prevention
- Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
- (2014) Howard Sofen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
- (2014) Charles W. Lynde et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Mendelian susceptibility to mycobacterial disease: Genetic, immunological, and clinical features of inborn errors of IFN-γ immunity
- (2014) Jacinta Bustamante et al. SEMINARS IN IMMUNOLOGY
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Association of Interleukin-12 Polymorphisms and Serum IL-12p40 Levels with Osteosarcoma Risk
- (2013) Junli Wang et al. DNA AND CELL BIOLOGY
- Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies
- (2013) C. Pouplard et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Potentially Functional Polymorphism in IL-23 Receptor and Risk of Acute Myeloid Leukemia in a Chinese Population
- (2013) Xifeng Qian et al. PLoS One
- Psoriasis Severity and the Prevalence of Major Medical Comorbidity
- (2013) Howa Yeung et al. JAMA Dermatology
- Associations between polymorphisms in IL-12A, IL-12B, IL-12Rβ1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer
- (2012) Yi-Peng Tao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients
- (2012) Sebastiano Gangemi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- IL-23R polymorphisms, HBV infection, and risk of hepatocellular carcinoma in a high-risk Chinese population
- (2012) Yan Xu et al. JOURNAL OF GASTROENTEROLOGY
- IL-12 and IL-23 Affect Photocarcinogenesis Differently
- (2012) Christian Jantschitsch et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
- (2012) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
- (2012) Sergei I. Grivennikov et al. NATURE
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin 23 Promotes Hepatocellular Carcinoma Metastasis via NF-Kappa B Induced Matrix Metalloproteinase 9 Expression
- (2012) Jian Li et al. PLoS One
- IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma
- (2012) HIDEYUKI SUZUKI et al. Oncology Letters
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
- (2011) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) B.E. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) A.B. Gottlieb et al. BRITISH JOURNAL OF DERMATOLOGY
- Anti-IL-23 Monoclonal Antibody Synergizes in Combination with Targeted Therapies or IL-2 to Suppress Tumor Growth and Metastases
- (2011) M. W. L. Teng et al. CANCER RESEARCH
- Potentially functional polymorphisms in IL-23 receptor and risk of esophageal cancer in a Chinese population
- (2011) Hongjun Chu et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
- (2011) Kenneth B. Gordon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis
- (2011) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- The TNF-Alpha-238 Polymorphism and Cancer Risk: A Meta-Analysis
- (2011) Ping Zhou et al. PLoS One
- Oesophageal squamous cell carcinoma in a young adult with IL-12R 1 deficiency
- (2010) M. Cardenes et al. JOURNAL OF MEDICAL GENETICS
- Economic burden of comorbidities in patients with psoriasis is substantial
- (2010) AB Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A nonsynonymous polymorphism in IL23R gene is associated with risk of gastric cancer in a Chinese population
- (2010) Jianjian Chen et al. MOLECULAR CARCINOGENESIS
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis
- (2010) M. W. L. Teng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-12 deficiency suppresses 12- O -tetradecanoylphorbol-13-acetate-induced skin tumor development in 7,12-dimethylbenz( a )anthracene-initiated mouse skin through inhibition of inflammation
- (2009) Som D. Sharma et al. CARCINOGENESIS
- Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with a Nested Case–Control Analysis
- (2009) Yolanda B. Brauchli et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3
- (2008) Jesse A. Berlin et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
- (2008) Alexa B. Kimball ARCHIVES OF DERMATOLOGY
- Interleukin-12 p40 gene (IL12B) polymorphisms and the risk of cervical caner in Korean women
- (2008) Seung-Su Han et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- IL-12 Deficiency Exacerbates Inflammatory Responses in UV-Irradiated Skin and Skin Tumors
- (2008) Syed M. Meeran et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now